Anonymous ID: 6683f9 Oct. 16, 2021, 5:06 a.m. No.14796076   🗄️.is 🔗kun

>>14795539

https://newswithviews.com/bill-clinton-and-the-deadly-arkansas-tainted-blood-scandal/

 

Bill Clinton was governor of Arkansas when the Canadian blood supply was contaminated in the mid-80s. He was familiar with the operations of the now defunct Health Management Associates (HMA). They were the Arkansas firm that was given a contract by Clinton’s state administration to provide medical care to prisoners.

 

In the process, HMA was also permitted by the state to collect prisoners’ blood and sell it elsewhere. The Governor was a friend of HMA president Leonard Dunn, a political ally, who boasted of the friendship in 1986 to Arkansas police who conducted a probe of the allegations HMA was providing poor medical care to inmates. He was appointed by Clinton to sit on the Arkansas Industrial Development Commission and served as finance chair of Clinton’s 1990 gubernatorial campaign. Later that same year, Dunn purchased the infamous Madison Guaranty Savings and Loan from Clinton’s business partner James McDougal (Whitewater).

 

In the early 80s, U.S. companies that fractionate blood products (separating the various components of blood plasma) had stopped buying prison blood because it was widely known that since many prisoners practiced unsafe sex or were intravenous drug users, they posed a high risk of carrying the AIDS virus.

 

However, HMA found a willing buyer in Continental Pharma, a Montreal blood broker, which in turn sold the plasma to Toronto based blood fractionator Connaught Laboratories. Connaught apparently did not realize the plasma had come from inmates.

Anonymous ID: 6683f9 Oct. 16, 2021, 5:51 a.m. No.14796183   🗄️.is 🔗kun   >>6186

>>14796177

>Pfizer and Theranos

from this article Pfizer didn't know either

https://www.theverge.com/2015/10/26/9618390/Theranos-glaxosmithkline-denies-partnership-pfizer-blood-test

 

Theranos, the hot Silicon Valley blood testing company that’s under scrutiny after a Wall Street Journal investigation suggested that the company's technology doesn't work as it should, has a lot of explaining to do. For over a year, multiple news outlets — including The New Yorker, The Washington Post, The Economist, and Fortune — have reported that Theranos earns a portion its income from large pharmaceutical companies Pfizer and GlaxoSmithKline, who reportedly use Theranos' tech to conduct clinical trials. But according to representatives from both companies who spoke to the Financial Times that information is factually incorrect.

 

"I cannot find any evidence that we've done business with them in recent years," a spokesperson for GSK told the Financial Times. When The Verge asked GSK about this, Mary Anne Rhyne, a spokeswoman for GSK told us that "GSK has not done any business with Theranos in the past two years." When we asked if the company had worked with Theranos before then, she told us that she didn't "have more information to share." A Theranos spokesperson told us that Theranos had engaged in clinical trial testing for GSK starting in 2008, however, but that was before Theranos opened its retail business.

 

Pfizer, on the other hand, told the Financial Times that the company's dealings with Theranos were limited. "We've done only very limited historical exploratory work with Theranos through a few pilot projects," the Pfizer representative said, "and we do not have any current or active projects with them."